Loo LiNa, Robinson Matthew K, Adams Gregory P
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Cancer J. 2008 May-Jun;14(3):149-53. doi: 10.1097/PPO.0b013e318173a5d5.
Antibodies have emerged as significant agents for the treatment of a number of diseases including cancer and autoimmunity. However, most of the antibodies currently used in clinical practice were developed from humanized or chimeric molecules based on mouse monoclonal antibodies. Recent advances in antibody selection and engineering techniques have led to the development of antibodies specific for highly conserved targets, the creation of novel antibody-based structures, significant improvements in affinity for target antigens, enhanced ability to engage immune effector functions, and the creation of fusion proteins with direct cytotoxic properties. This review provides an overview of the techniques that we expect will have the greatest impact on the field of antibody engineering.
抗体已成为治疗包括癌症和自身免疫性疾病在内的多种疾病的重要药物。然而,目前临床实践中使用的大多数抗体是基于小鼠单克隆抗体开发的人源化或嵌合分子。抗体筛选和工程技术的最新进展导致了针对高度保守靶点的特异性抗体的开发、新型抗体结构的创建、对靶抗原亲和力的显著提高、参与免疫效应功能能力的增强以及具有直接细胞毒性特性的融合蛋白的创建。本综述概述了我们预计将对抗体工程领域产生最大影响的技术。